The University of Houston is at the forefront of advancing cancer research and immunotherapy with its newly established Cancer Immunotherapy Biomarker Core (CIBC), backed by a significant $3 million grant from the Cancer Prevention and Research Institute of Texas (CPRIT). This ambitious initiative aims to drastically enhance biomarker discovery processes, providing unparalleled proteomic screening capabilities and expanding research infrastructure across Texas. By integrating cutting-edge proteomic technologies and fostering collaboration among immunology researchers, the UH CIBC offers transformative potential for cancer diagnosis, treatment personalization, and patient surveillance throughout the state and beyond.
Targeted proteomics lies at the heart of this initiative, offering a revolutionary means to unravel the complex protein signatures involved in cancer biology. Unlike traditional approaches that often examine a limited subset of proteins, the UH CIBC utilizes a highly multiplexed proteomic screening platform capable of detecting and quantifying over 11,000 proteins simultaneously within a single body fluid sample. This expansive scope enables researchers to identify novel biomarkers with unprecedented depth, creating new avenues for early cancer detection and precise immunotherapy targeting.
The core facility also boasts a complementary 21,000-plex protein array platform, which facilitates global analysis of autoantibodies and ligands across the entire human proteome. Autoantibodies often provide critical insights into immune system dysfunction and tumor immunogenicity. Investigating these autoantibodies at scale empowers scientists to delineate intricate immune responses and identify neoantigens—the mutated or aberrantly expressed proteins targeted by the immune system—thereby accelerating the development of next-generation immunotherapies.
Cancer immunotherapy has emerged as a revolutionary treatment paradigm by harnessing the immune system’s intrinsic ability to recognize and eradicate malignant cells. Unlike traditional therapies that directly target tumor cells with chemotherapy or radiation, immunotherapy “trains” the immune system to identify cancer-specific proteins and mount a targeted attack, minimizing collateral damage to healthy tissues. However, a major bottleneck in this precision medicine landscape is the identification of biomarkers that can predict immunotherapy responsiveness and monitor therapeutic outcomes effectively.
Dr. Chandra Mohan, a leading biomedical engineer and project director of the UH CIBC, emphasizes the transformative potential of better biomarker identification. With over 20 years of experience developing diagnostic arrays, Dr. Mohan articulates that more refined biomarkers will accelerate early cancer detection, enhance prognostication accuracy, and provide real-time insights into disease progression and treatment responsiveness. These clinical improvements could ultimately lead to the discovery of more effective and less toxic cancer therapies while reducing morbidity and mortality rates on a population scale.
Co-leading the core is immunologist Dr. Weiyi Peng, whose expertise lies in dissecting T cell-mediated anti-tumor immune pathways through genetic screening and preclinical models. Her leadership in the Drug Discovery Institute Immunology Core, which supports over 100 University of Houston researchers, positions the UH CIBC as a hub of interdisciplinary innovation. Dr. Peng’s work complements the core’s mission by integrating immunological biomarker research with proteomic technologies to unravel the complex dynamics of tumor-immune interactions.
The UH CIBC’s establishment addresses crucial gaps in Texas’ cancer research landscape, being the first facility statewide to offer these advanced, high-throughput proteomic platforms at a subsidized cost. By providing accessible and affordable biomarker screening services, the core democratizes cutting-edge research capabilities, inviting broad participation from academic institutions, healthcare providers, and biotech companies throughout the region. This inclusive approach is expected to accelerate the pace of discovery and translation in cancer immunotherapy.
Aside from offering comprehensive proteomic screening, the core is dedicated to education and technology adoption. It plans to conduct workshops, seminars, and collaborative projects to familiarize Texas researchers with contemporary proteomic methodologies. This educational outreach ensures that emerging scientists and clinicians remain well-equipped with the technical proficiency necessary to harness proteomics for biomarker discovery, ultimately fostering a statewide ecosystem of innovation in cancer immunotherapy.
The technological sophistication of the UH CIBC platforms is noteworthy. The 11,000-plex targeted proteomic screen utilizes mass spectrometry coupled with highly specific peptide libraries, enabling not only the identification but also precise quantification of protein biomarkers at extremely low abundance levels. Such sensitivity is critical when analyzing complex biological fluids like blood or cerebrospinal fluid, where proteins of interest may be present in minute quantities, yet hold significant diagnostic or prognostic value.
Furthermore, the 21,000-plex protein array incorporates recombinant human proteins displayed on chip surfaces, allowing for high-throughput screening of antibody binding interactions with unparalleled proteome-wide coverage. This platform is invaluable for autoantibody discovery, providing insights into autoimmune responses elicited by tumor cells and contributing to the identification of tumor-specific antigens. It also facilitates therapeutic target validation by assessing ligand-receptor interactions on a proteome scale.
The UH CIBC’s integration into the University of Houston’s Drug Discovery Institute amplifies its impact. This alignment facilitates synergistic collaborations between engineering, immunology, and oncology experts, accelerating translational research pipelines from biomarker discovery to drug development and clinical trials. The core’s resources complement existing initiatives aimed at unraveling the genetic and molecular underpinnings of cancer, enabling multi-omic approaches with greater precision and scale.
Dr. Claudia Neuhauser, University of Houston’s vice president for research, remarked that the core’s immunology-centered focus aligns seamlessly with the university’s strategic priorities. The facility not only augments research infrastructure but also fosters interdisciplinary efforts critical for tackling complex diseases like cancer. By bolstering immunological research capabilities, the CIBC contributes to positioning the University of Houston and Texas as national leaders in cancer immunotherapy innovation.
The funding from CPRIT highlights Texas’ commitment to pioneering cancer research. CPRIT has established a rigorous peer-review system ensuring that only meritorious proposals with the highest potential for impact receive funding. This grant to the UH CIBC underscores the strategic vision of fostering infrastructure that empowers researchers to uncover novel biomarkers and develop targeted therapies, ultimately improving clinical outcomes for cancer patients throughout the state and beyond.
In summary, the University of Houston’s Cancer Immunotherapy Biomarker Core represents a landmark investment in the future of cancer biology and immunotherapy. By combining state-of-the-art targeted proteomic technologies, expert leadership, and a collaborative spirit, the CIBC is poised to transform biomarker discovery, refine immunotherapy targeting, and accelerate translational cancer research. As the fight against cancer enters a new era defined by precision medicine, this facility stands as a beacon of innovation, offering hope for earlier diagnosis, more effective treatments, and improved survival rates for patients facing this formidable disease.
—
Subject of Research: Cancer Immunotherapy Biomarker Discovery and Targeted Proteomic Technologies
Article Title: University of Houston Launches Cutting-Edge Cancer Immunotherapy Biomarker Core To Revolutionize Proteomic Screening and Immunotherapy Research
News Publication Date: May 27, 2024
Web References:
https://mediasvc.eurekalert.org/Api/v1/Multimedia/3b0ce0b7-b437-49bb-87eb-36b68babcd68/Rendition/low-res/Content/Public
Image Credits: University of Houston
Keywords: Cancer immunotherapy, targeted proteomics, biomarker discovery, UH CIBC, Cancer Prevention and Research Institute of Texas, mass spectrometry, protein array, autoantibodies, neoantigens, biomedical engineering, immunology, oncology
